Millipore Sigma Vibrant Logo

ASK07 p53 Antibody Sampler Kit

p53 Antibody Sampler Kit MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
ASK07
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species Reactivity
      A Broad Range Of Species
      Description
      Overview

      This product has been discontinued.



      20 µg of various p53 antibodies. Includes Cat. Nos. OP03, OP09, OP29, OP32, OP33, and OP43.
      Please see individual product descriptions for more information on applications and species reactivity.
      Catalogue NumberASK07
      Brand Family Calbiochem®
      References
      ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
      Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
      Barak, Y., et al. 1993. EMBO J. 12, 461.
      Cattoretti, G., et al. 1993. J. Pathol. 171, 83.
      Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
      Kastan, M.B., et al. 1992. Cell 71, 587.
      Lane, D.P. 1992. Nature 358, 15.
      Cordon-Cardo, C., et al. 1991. Cancer Res. 54, 794.
      Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.
      Product Information
      FormLiquid
      Formulation20 µg of each antibody in 200 µl (100 µg/ml) of 0.05 M sodium phosphate buffer containing 0.1% sodium azide and 0.2% gelatin.
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application NotesImmunoblotting (see characteristics below)
      Paraffin Sections (see characteristics below)
      Frozen Sections (see characteristics below)
      Immunoprecipitation (see characteristics below)
      Immunofluorescence (see characteristics below)
      Application CommentsCat. No. OP03, Cat. No. OP09 and Cat. No. OP43 are pantropic (detect both mutant and wild-type p53). Cat. No. OP32 and Cat. No. OP33 detect only wild-type p53. Cat. No. OP29 detects only mutant p53 under nondenaturing conditions (immunoprecipitation, immunofluorescence and frozen sections) but is pantropic under denaturing conditions (immunoblotting and paraffin sections). Wild-type p53 has a short half-life and is present in low amounts; thus, it can be difficult to detect. For immunoprecipitations, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53, and short incubation times with 35S-Met (≤1 h) will help reduce background. To increase sensitivity in a western blot, load more sample (i.e. 150 mg total cell protein per lane) and/or increase the concentration of primary antibody. To minimize extra bands in a western blot, reduce the concentration of both primary and secondary antibodies. Breast carcinoma can be used as a positive control (40% will be positive) for frozen and paraffin sections. p53 (Ab-3) will give light staining of paraffin sections after pretreating with 6M urea for 10 min at 95°C. Ab-4 and Ab-5 have been used in frozen sections but are not recommended for immunoblotting. All antibodies in this kit are too dilute to be used in gel shift assays.
      Biological Information
      Species Reactivity
      • A Broad Range Of Species
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      ASK07 0

      Documentation

      p53 Antibody Sampler Kit Certificates of Analysis

      TitleLot Number
      ASK07

      References

      Reference overview
      El-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
      Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
      Barak, Y., et al. 1993. EMBO J. 12, 461.
      Cattoretti, G., et al. 1993. J. Pathol. 171, 83.
      Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
      Kastan, M.B., et al. 1992. Cell 71, 587.
      Lane, D.P. 1992. Nature 358, 15.
      Cordon-Cardo, C., et al. 1991. Cancer Res. 54, 794.
      Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision20-August-2007 RFH
      ApplicationImmunoblotting (see characteristics below)
      Paraffin Sections (see characteristics below)
      Frozen Sections (see characteristics below)
      Immunoprecipitation (see characteristics below)
      Immunofluorescence (see characteristics below)
      BackgroundThe human p53 tumor suppressor gene encodes a 393 amino acid phosphoprotein that exhibits sequence-specific DNA binding and directly interacts with various cellular and viral proteins. p53 is the most commonly mutated gene in human cancer, with the majority of the mutations being amino acid substitutions. The normal function of p53 is to effect cell cycle arrest at the G1 and G2 checkpoints in response to DNA damage. This checkpoint function is executed by accumulation of p53 followed by induction of the GADD45, WAF1 and MDM2 genes. The current model of p53 function postulates that p53 senses DNA damage and arrests the cell cycle in either the G1 or G2 phases to allow DNA repair to take place. If repair is not successful, p53 initiates programmed cell death, thus preventing the propagation of genetic defects to successive generations of cells.
      Speciesa broad range of species
      FormLiquid
      Formulation20 µg of each antibody in 200 µl (100 µg/ml) of 0.05 M sodium phosphate buffer containing 0.1% sodium azide and 0.2% gelatin.
      Preservative≤0.1% sodium azide
      CommentsCat. No. OP03, Cat. No. OP09 and Cat. No. OP43 are pantropic (detect both mutant and wild-type p53). Cat. No. OP32 and Cat. No. OP33 detect only wild-type p53. Cat. No. OP29 detects only mutant p53 under nondenaturing conditions (immunoprecipitation, immunofluorescence and frozen sections) but is pantropic under denaturing conditions (immunoblotting and paraffin sections). Wild-type p53 has a short half-life and is present in low amounts; thus, it can be difficult to detect. For immunoprecipitations, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53, and short incubation times with 35S-Met (≤1 h) will help reduce background. To increase sensitivity in a western blot, load more sample (i.e. 150 mg total cell protein per lane) and/or increase the concentration of primary antibody. To minimize extra bands in a western blot, reduce the concentration of both primary and secondary antibodies. Breast carcinoma can be used as a positive control (40% will be positive) for frozen and paraffin sections. p53 (Ab-3) will give light staining of paraffin sections after pretreating with 6M urea for 10 min at 95°C. Ab-4 and Ab-5 have been used in frozen sections but are not recommended for immunoblotting. All antibodies in this kit are too dilute to be used in gel shift assays.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
      Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
      Barak, Y., et al. 1993. EMBO J. 12, 461.
      Cattoretti, G., et al. 1993. J. Pathol. 171, 83.
      Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
      Kastan, M.B., et al. 1992. Cell 71, 587.
      Lane, D.P. 1992. Nature 358, 15.
      Cordon-Cardo, C., et al. 1991. Cancer Res. 54, 794.
      Kastan, M.B., et al. 1991. Cancer Res. 51, 6304.